FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2414963457> ?p ?o ?g. }

• W2414963457 abstract "Background There is not enough data on the dosing patterns and switching rates of the most frequently used TNFis infliximab, adalimumab and etanercept in Turkey. Objectives The aim of this retrospective chart review is to compare the proportion of rheumatoid arthritis (RA) subjects requiring treatment modification between the TNFis (etanercept, infliximab and adalimumab). Methods Inclusion criterias; a) Consecutive patients diagnosed with RA who were newly started on TNFis as the first biologic treatment. b) Have received continuous treatment with the index TNFi (the date of initial prescription of a TNFi is considered index date and the TNFi itself is the index TNFi) for at least 3 months following the index date and with a biologic (either the index drug or other biologic to which he/she was switched due to inefficacy) for at least 18 months. DMARDs and corticosteroids doses, dosing regimens and reasons for dose changes collected for 18 months following the index date. The primary end point is the proportion of patients with treatment modification which is defined as either one of the following: The first occurrence of any upward adjustment in dose or dosing frequency of each TNFi from the label/indicated dose and unit of time (etanercept 25 milligram [mg] biweekly or 50 mg once weekly, adalimumab 40 mg once every other week or infliximab 3mg/kilogram [kg] every 8 weeks after the 3rd infusion) within the 12 month period following index date. The first occurrence of any switch to another biologic agent due to inefficacy or loss of efficacy Results Overall 400 patients (79.3% female) were enrolled to this study. TNFi drugs were etanercept (240 patients), adalimumab (80 patients) and infliximab (80 patients) respectively. Mean age was 53±12 years old, mean disease duration was 11.3±7.5 years. Anti-CCP antibody was positive at 115/201 (57.2%), and rheumatoid factor was positive at 178/311 (57.2%) of patients. Baseline DAS-28 score was 5.75±0.79, baseline ESR and CRP were 45±26 mm/hour and 3.4±2.8 mg/dl, respectively. The distribution of modifications such as change of TNFi duration or dosage (modification 1), change of TNFi due to inefficacy or lost of efficacy (modification 2), increase of DMARDs or steroid dosage (modification 3) and add of DMARDs or steroid (modification 4) were shown at table 1. Conclusions Dose escalation was prominent at infliximab than other anti-TNF drugs. Patients with infliximab also had more frequent switch of TNFi due to inefficacy or loss of efficacy. However, increase or add of DMARD or steroid were similar at whole anti-TNF drugs. Acknowledgements This study was supported by Phizer, Inc. Disclosure of Interest None declared" @default.
• W2414963457 created "2016-06-24" @default.
• W2414963457 creator A5003684500 @default.
• W2414963457 creator A5013802254 @default.
• W2414963457 creator A5014573608 @default.
• W2414963457 creator A5017389872 @default.
• W2414963457 creator A5019796937 @default.
• W2414963457 creator A5028241466 @default.
• W2414963457 creator A5032970295 @default.
• W2414963457 creator A5050410636 @default.
• W2414963457 creator A5073659171 @default.
• W2414963457 creator A5084643359 @default.
• W2414963457 creator A5088741937 @default.
• W2414963457 date "2015-06-01" @default.
• W2414963457 modified "2023-10-18" @default.
• W2414963457 title "AB0432 Dose Escalation and Switching Patterns of Anti-TNF Drugs in Rheumatoid Arthritis: A Retrospective Chart – Review Study in Turkey: Table 1." @default.
• W2414963457 doi "https://doi.org/10.1136/annrheumdis-2015-eular.6029" @default.
• W2414963457 hasPublicationYear "2015" @default.
• W2414963457 type Work @default.
• W2414963457 sameAs 2414963457 @default.
• W2414963457 citedByCount "0" @default.
• W2414963457 crossrefType "journal-article" @default.
• W2414963457 hasAuthorship W2414963457A5003684500 @default.
• W2414963457 hasAuthorship W2414963457A5013802254 @default.
• W2414963457 hasAuthorship W2414963457A5014573608 @default.
• W2414963457 hasAuthorship W2414963457A5017389872 @default.
• W2414963457 hasAuthorship W2414963457A5019796937 @default.
• W2414963457 hasAuthorship W2414963457A5028241466 @default.
• W2414963457 hasAuthorship W2414963457A5032970295 @default.
• W2414963457 hasAuthorship W2414963457A5050410636 @default.
• W2414963457 hasAuthorship W2414963457A5073659171 @default.
• W2414963457 hasAuthorship W2414963457A5084643359 @default.
• W2414963457 hasAuthorship W2414963457A5088741937 @default.
• W2414963457 hasConcept C126322002 @default.
• W2414963457 hasConcept C167135981 @default.
• W2414963457 hasConcept C17991360 @default.
• W2414963457 hasConcept C2777138892 @default.
• W2414963457 hasConcept C2777226972 @default.
• W2414963457 hasConcept C2777288759 @default.
• W2414963457 hasConcept C2777575956 @default.
• W2414963457 hasConcept C2779338263 @default.
• W2414963457 hasConcept C2779605438 @default.
• W2414963457 hasConcept C2780132546 @default.
• W2414963457 hasConcept C2780653079 @default.
• W2414963457 hasConcept C71924100 @default.
• W2414963457 hasConceptScore W2414963457C126322002 @default.
• W2414963457 hasConceptScore W2414963457C167135981 @default.
• W2414963457 hasConceptScore W2414963457C17991360 @default.
• W2414963457 hasConceptScore W2414963457C2777138892 @default.
• W2414963457 hasConceptScore W2414963457C2777226972 @default.
• W2414963457 hasConceptScore W2414963457C2777288759 @default.
• W2414963457 hasConceptScore W2414963457C2777575956 @default.
• W2414963457 hasConceptScore W2414963457C2779338263 @default.
• W2414963457 hasConceptScore W2414963457C2779605438 @default.
• W2414963457 hasConceptScore W2414963457C2780132546 @default.
• W2414963457 hasConceptScore W2414963457C2780653079 @default.
• W2414963457 hasConceptScore W2414963457C71924100 @default.
• W2414963457 hasLocation W24149634571 @default.
• W2414963457 hasOpenAccess W2414963457 @default.
• W2414963457 hasPrimaryLocation W24149634571 @default.
• W2414963457 isParatext "false" @default.
• W2414963457 isRetracted "false" @default.
• W2414963457 magId "2414963457" @default.
• W2414963457 workType "article" @default.